

## Universal Influenza Immunization Program (UIIP) Primary Care 2020/2021

**Attention:** Physicians; Nurse Practitioners; Walk-in Clinics/Urgent Care Clinics; Correctional Facilities; Participating Health Care Agencies; Beausoleil Health Centre; Rama First Nation, Moose Deer Point First Nation; NSM LHIN; Central LHIN

**Date:** September 23 2020

---

### Key Points

- **We will not be accepting any influenza vaccine orders prior to October 1, 2020.** Orders received prior to this date will not be processed/filled.
- **We ask that no large clinics are booked prior to November 2<sup>nd</sup>, 2020** (to help ensure we have adequate vaccine supply).
- High-Dose Trivalent Inactivated Vaccine (HD TIV) (Fluzone® High-Dose) should only be given to those 65 years and older. However, immunization should not be delayed if HD TIV is not readily available.
  - Pharmacies are being supplied flu vaccine including the HD TIV directly from the province, resulting in less HD TIV being distributed to local public health units for HCPs
  - If there is inadequate HD TIV for your patients, you may want to direct them to their local pharmacies.
- Quadrivalent Inactivated Vaccine (QIV) products:
  - FluLaval® Tetra: For anyone 6 months of age and older
  - Fluzone® Quadrivalent: For anyone 6 months of age and older
  - Flucelvax® Quad: For anyone 9 years of age and older
- Nasal spray vaccine (Flumist® Quadrivalent) will not be publicly funded for the 2020/2021 influenza season.
- Vaccinating children: Children 6 months to less than 9 years of age receiving seasonal influenza vaccine for the first time in their life should be given 2 doses of vaccine, with a minimum interval of 4 weeks between doses.
- Fluzone® High-Dose will be available through primary care providers (physicians and nurse practitioners); participating retirement homes; long-term care homes and hospitals; and new for this year, participating pharmacies.
- Flucelvax®Quad (distributed to pharmacies only) is a mammalian cell culture based, inactivated seasonal influenza vaccine that has recently been authorized for use in Canada. Flucelvax®Quad is considered effective, immunogenic and safe in adults and children 9 years of age and older. It has a comparable immunogenicity and safety profile to egg-based influenza vaccines already licensed in Canada. See National Advisory Committee for Immunization (NACI) [supplemental statement](#)<sup>i</sup> for additional information.

### Vaccine Ordering

As in previous years, the health unit will only receive part of their influenza vaccine allocation in the month October. Every effort will be made to distribute the vaccine as fairly and equitably as possible to ensure that all area health care providers (HCPs) receive some supply to immunize their most vulnerable patients.



Throughout the month of October, HCPs are to be immunizing only those who meet the high risk criteria outlined below on page 4. Once the annual UIIP is officially launched by the MOHLTC (late October/early November), vaccine can be administered to the general population. To assist with planning, the following allocation and timelines have been established for vaccine ordering:

Health Care Provider	Order Due By	Ready for Pick up	Product	Maximum Quantity
Primary Care – <u>High Risk only</u>	Wed Oct 7 <sup>th</sup>	Wed Oct 14 <sup>th</sup>	QIV HD TIV	Up to 60 doses per MD/NP Based on local supply
Reorders	Wed Oct 14 <sup>th</sup>	Wed Oct 21 <sup>st</sup>	QIV HD TIV	Up to 50 doses per MD/NP Based on local supply

#### **Other Important Ordering Reminders:**

- If you were required to prequalify for vaccine and recently had your fridge inspection, you must submit five consecutive days of twice daily fridge temperatures between 2-8°C before your initial order can be filled.
- Each time you order influenza vaccine, you must submit by fax (705-726-3962) your temperature log sheet(s) for the previous four weeks. Temperature readings must be done and recorded in the log book twice a day every day. These temperature log sheets are reviewed by the SMDHU prior to vaccine being released.
- The package sizes of some products may also impact fridge space. Health unit staff may adjust orders taking into account your current inventory, the size of your vaccine fridge and current vaccine supply.
- If there is a reason you are ordering a large amount of vaccine (i.e. you have a clinic booked), please note this on the order form so that staff can take this into account when reviewing your order.
- Unfortunately, we do not have a way of tracking balances remaining that were not filled on previous orders. If you require additional vaccine beyond what you received in your order, you will need to submit another vaccine order along with your updated temperature logs.
- Only influenza vaccine orders submitted on this year's Influenza Vaccine Order Form will be filled. Be sure to choose the appropriate form based on which health unit office you pick up vaccine from. ([Barrie, Collingwood, Cookstown or Midland<sup>ii</sup>](#)) or ([Gravenhurst, Huntsville or Orillia<sup>iii</sup>](#)).

As recommended by the World Health Organization (WHO), the following strains are included in this year's vaccines:

#### **Quadrivalent vaccine – egg based vaccines:**

- A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus
- A/Hong Kong/2671/2019 (H3N2)-like virus
- B/Washington/02/2019 (B/Victoria lineage)-like virus
- B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

#### **Quadrivalent vaccine: Cell – recombinant-based vaccines:**

- A/Hawaii/70/2019 (H1N1) pdm09-like virus
- A/Hong Kong/45/2019 (H3N2)-like virus
- B/Washington/02/2019 (B/Victoria lineage)-like virus
- B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

#### **Trivalent vaccine – egg based vaccine:**

- A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus
- A/Hong Kong/2671/2019 (H3N2)-like virus
- B/Washington/02/2019 (B/Victoria lineage)-like virus

The NACI [Statement on Seasonal Influenza Vaccine for 2020-2021<sup>iv</sup>](#) can be found on the Public Health Agency of Canada website.

To access product monographs for the publicly funded influenza vaccine products, visit the [Health Canada – Drug Product Database Online Query](#)<sup>v</sup> website and enter the product name to search.

The NACI publication on [Guidance for influenza vaccine delivery in the presence of COVID-19](#)<sup>vi</sup> can be found on the Public Health Agency of Canada website.

### Which vaccines are individuals eligible to receive in Ontario this year?

Age Group	QIV			High-Dose TIV
	FluLaval® Tetra	Fluzone® Quadrivalent	Flucelvax®Quad (pharmacies only)	Fluzone® High-Dose
6 months through 9 years	■	■		
9 years up to and including 64 years	■	■	■	
≥65 years *	■	■	■	■

\*NOTE: NACI has not identified any preference between QIV and HD TIVE products for individuals 65 years of age and older.

	Quadrivalent Inactivated Vaccine			High-Dose Trivalent Inactivated Vaccine				
UIIP Abbreviation	QIV			High-dose TIV				
NACI Abbreviation	IIV4-SD		IIV4-cc	IIV3-HD				
Vaccine product	FluLaval®Tetra	Fluzone® Quadrivalent	Flucelvax®Quad	Fluzone® High-Dose				
Micrograms of HA	15 µg	15 µg	15 µg	60 µg				
Dosage	0.5 ml	0.5 ml	0.5 ml	0.5 ml				
Format	Multidose vial	<ul style="list-style-type: none"> <li>• Multidose vial (MDV)</li> <li>• Pre-filled syringe (PFS)</li> </ul>	Pre-filled syringe	Pre-filled syringe				
Post Puncture Shelf life	28 days	<table border="1"> <tr> <td>MDV</td> <td>28 days</td> </tr> <tr> <td>PFS</td> <td>N/A</td> </tr> </table>	MDV	28 days	PFS	N/A	N/A	N/A
MDV	28 days							
PFS	N/A							
Route	Intramuscular injection	Intramuscular injection	Intramuscular injection	Intramuscular Injection				
Age indication	≥6 months	≥6 months	≥9 years	≥65 years				
Most common allergens	<ul style="list-style-type: none"> <li>• Egg protein*</li> <li>• Thimerosal</li> </ul>	<table border="1"> <tr> <td>MDV</td> <td> <ul style="list-style-type: none"> <li>• Egg protein*</li> <li>• Thimerosal</li> </ul> </td> </tr> <tr> <td>PFS</td> <td> <ul style="list-style-type: none"> <li>• Egg protein*</li> </ul> </td> </tr> </table>	MDV	<ul style="list-style-type: none"> <li>• Egg protein*</li> <li>• Thimerosal</li> </ul>	PFS	<ul style="list-style-type: none"> <li>• Egg protein*</li> </ul>	Does NOT contain egg protein	Egg protein*
MDV	<ul style="list-style-type: none"> <li>• Egg protein*</li> <li>• Thimerosal</li> </ul>							
PFS	<ul style="list-style-type: none"> <li>• Egg protein*</li> </ul>							

\*According to NACI, egg-allergic individuals may be vaccinated against influenza using the full dose of any appropriate product, including QIV, Q-LAIV and HD TIV.

**Important Notes:**

- Fluzone® Quadrivalent and Fluzone® High-Dose are different products. Fluzone® High-Dose is only authorized for those 65 years of age and over. Please use caution when administering Fluzone® products to ensure that the right vaccine is being administered to the right person.
- Trained pharmacists can only administer publicly funded influenza vaccine to individuals 5 years of age and older.

<b>Recommended needle gauge and length for vaccine recipient: Intramuscular Injections (IM)</b>		
	<b>Infants, Toddlers and Older children</b>	<b>Adolescents and Adults</b>
<b>Needle gauge</b>	22-25	22-25
<b>Needle length</b>	7/8 – 1 inch	1 -1 1/2 inch

Please ensure stock of appropriate sized syringes and needles. Pre-filled syringes do not come with needle tips.

**Publicly Funded Influenza vaccine is only initially to be administered to those who meet the following high risk criteria:**

Individuals at high risk of influenza-related complications or more likely to require hospitalization which includes:

- All pregnant women (at any stage of pregnancy)
- People who are residents of LTCH or other chronic care facilities
- People ≥65 years of age
- All children 6-59 months of age
- Indigenous peoples
- Adults or children with chronic health conditions as follows:
  - cardiac or pulmonary disorders
  - diabetes mellitus or other metabolic disease
  - cancer
  - conditions which compromise the immune system
  - renal disease
  - anemia or hemoglobinopathy
  - neurologic or neurodevelopmental conditions
  - morbid obesity (body mass index of ≥40)
  - children 6 months to 18 years of age undergoing treatment with acetylsalicylic acid for long periods

Individuals capable of transmitting influenza to those at high risk, which includes:

- Health care workers and other care providers in facilities and community settings
- Household contacts (adults and children) of individuals at high risk of influenza related complications (includes household contacts of infants less than 6 months of age, and household members expecting a newborn during the influenza season)
- Persons who provide care to children ≤59 months of age
- Those who provide services in a closed/relatively closed setting to persons at high risk (e.g. crew on a ship)

In addition, influenza vaccine is strongly recommended for individuals that work in essential community services and the swine and poultry industry.

**HD TIV and non-high dose Quadrivalent Influenza Vaccine (QIV) are available this year for those 65 years and older**

**The choice between the HD TIV vs non-high dose QIV rests with the clinician and patient. Both are acceptable. Given the available information at this time, SMDHU recommends the HD TIV because of its higher effectiveness in preventing influenza A morbidity in those 65 years and older. However, immunization should not be delayed if your preferred vaccine is unavailable.**

The following are relevant considerations when vaccinating adults 65 years of age and over.

**Influenza A:**

- The burden of influenza A/H3N2 is higher in adults 65 years of age and over compared to other strains. Seasons with circulation of influenza A/H3N2 result in more outbreaks, hospitalizations and deaths, which occur most commonly among older adults.
- The high-dose TIV provides better protection than standard-dose TIV, including against the A/H3N2 strain as demonstrated in a large randomized trial. The trial showed high-dose TIV to be 24.2% (95% CI: 9.7% to 36.5%) more effective compared to standard dose TIV in preventing laboratory-confirmed influenza. The A/H3N2 strain is the same in the standard-dose TIV and standard-dose QIV vaccines, so similar enhanced protection against the A/H3N2 found for high-dose TIV is also expected when compared to the standard dose QIV.

**Influenza B:**

- Although the high-dose TIV contains one less B strain than in the QIV, B strains occur less frequently in adults 65 years of age and over than A strains.
- There may be cross protection against B lineages, such that the TIV vaccine that contains B/Victoria may offer some protection against B/Yamagata and vice versa, although this may not always occur. Therefore, high-dose TIV may afford some protection against the B lineage not included in that vaccine.

**Safety:**

QIV and high-dose TIV are expected to have a generally similar safety profile. Local reactions and systemic adverse events occur somewhat more frequently with high-dose TIV than standard-dose TIV. The systemic reactions are described as generally mild and short lived.

**For more information, support materials and forms refer to the following websites:**

- [www.smdhu.org/pcportal](http://www.smdhu.org/pcportal)
- <http://www.ontario.ca/flu>

**Reporting of Adverse Events**

An *Adverse Event Following Immunization (AEFI)* form must be filled out and faxed (705-726-3962) to the Immunization Program for follow-up immediately following any unexpected adverse events.

If you have any questions regarding the vaccine ordering process please contact the Immunization Program at 705-721-7520 or toll free at 1-877-721-7520 ext. 8808.

If you are calling to report a Cold Chain Failure, or have any questions regarding influenza vaccines please contact the Immunization Program at 705-721-7520 or toll free at 1-877-721-7520 ext. 8806.

<sup>i</sup> <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/mammalian-cell-culture-based-influenza-vaccines.html>

<sup>ii</sup> [https://www.simcoemuskokahealth.org/docs/default-source/jfy-health-care-professionals/200917-influenza\\_barrie\\_vaccineorderform\\_20200914.pdf?sfvrsn=2](https://www.simcoemuskokahealth.org/docs/default-source/jfy-health-care-professionals/200917-influenza_barrie_vaccineorderform_20200914.pdf?sfvrsn=2)

<sup>iii</sup> [https://www.simcoemuskokahealth.org/docs/default-source/jfy-health-care-professionals/200917-influenza\\_gh\\_vaccineorderform\\_20200914.pdf?sfvrsn=2](https://www.simcoemuskokahealth.org/docs/default-source/jfy-health-care-professionals/200917-influenza_gh_vaccineorderform_20200914.pdf?sfvrsn=2)

<sup>iv</sup> <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021.html>

<sup>v</sup> <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>

<sup>vi</sup> <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-influenza-vaccine-delivery-covid-19.html>